Genetic Polymorphisms of the Epidermal Growth Factor and Related Receptor in Non-Small Cell Lung Cancer—A Review of the Literature

CME Activity Information
Release Date:	February 12, 2007
Most Recent Review:	February 12, 2007*
Most Recent Update:	February 12, 2007
Date Credit Expires:	February 12, 2009
Time to Complete:	1 hour
Medium:	Internet Online
*Click here to learn more about our review process.

Instructions for Participation

1. Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
2. Study the educational activity
3. Complete the CME quiz and evaluation
4. After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate

   *The CME quiz and evaluation must be completed by February 12, 2009, in order to receive the credit or participation certificate.

1. Describe the role played by EGF and EGFR in lung carcinogenesis.
2. Discuss how different polymorphic alleles from the EGF and EGFR genes may affect drug response.
3. Evaluate the value of determining the presence of EGF and EGFR polymorphisms in NSCLC patients for daily clinical practice.

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process: http://theoncologist.alphamedpress.org/misc/ifora.shtml. All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.

Credentials: Department of Medical Oncology, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal; ICBAS, Abel Salazar Institute for Biomedical Sciences, University of Porto, Porto, Portugal; Molecular Oncology—CI, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal. Telephone: 00351-22-5084000; Fax: 00351-22-5084008; E-mail: amfaraujo{at}netcabo.pt.
Disclosures: The author has indicated no relevant commercial relationships.

Ricardo Ribeiro, M.D.

Credentials: ICBAS, Abel Salazar Institute for Biomedical Sciences, University of Porto, Porto, Portugal; Molecular Oncology—CI, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal.
Disclosures: The author has indicated no relevant commercial relationships.

Isabel Azevedo, M.D.

Credentials: Department of Medical Oncology, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal.
Disclosures: The author has indicated no relevant commercial relationships.

Ana Coelho, M.D.

Credentials: Molecular Oncology—CI, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal.
Disclosures: The author has indicated no relevant commercial relationships.

Marta Soares, M.D.

Credentials: Department of Medical Oncology, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal.
Disclosures: The author has indicated no relevant commercial relationships.

Berta Sousa, M.D.

Credentials: Department of Medical Oncology, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal.
Disclosures: The author has indicated no relevant commercial relationships.

Daniela Pinto, M.D.

Credentials: Molecular Oncology—CI, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal.
Disclosures: The author has indicated no relevant commercial relationships.

Carlos Lopes, M.D.

Credentials: ICBAS, Abel Salazar Institute for Biomedical Sciences, University of Porto, Porto, Portugal; Molecular Oncology—CI, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal.
Disclosures: The author has indicated no relevant commercial relationships.

Rui Medeiros, M.D.

Credentials: ICBAS, Abel Salazar Institute for Biomedical Sciences, University of Porto, Porto, Portugal; Molecular Oncology—CI, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal.
Disclosures: The author has indicated no relevant commercial relationships.

Giorgio V. Scagliotti, M.D.

Credentials: Department of Clinical and Biological Sciences, University of Torino, Torino, Italy.
Disclosures: The author has indicated no relevant commercial relationships.

• Take this course